Business Wire

TRADE-EXTENSIONS

7.12.2016 15:45:52 CET | Business Wire | Press release

Share
Trade Extensions: Consumers put their trust in manufacturers and retailers to look after suppliers

Consumers put their trust in manufacturers and retailers to look after suppliers and are prepared to pay more to shop at retailers who treat their suppliers better.

The latest research from sourcing with optimisation specialist Trade Extensions reveals the implicit trust consumers place in manufactures and retailers to look after supplier welfare and the penalties retailers face should they betray this trust.

The research reveals that while only 20% of UK and US consumers ranked suppliers as the most important consideration at the point of purchase, 76% feel manufacturers and retailers have a responsibility to look after suppliers and only 9% feel that manufacturers and retailers have no responsibility.

This implicit trust that consumers place in manufacturers and retailers is further demonstrated by the fact that 75% say they would prefer to shop at a retailer if it can demonstrate they treat their suppliers better and over 75% of consumers are prepared to pay a premium. In addition, only 25% of consumers feel the government should get involved in supplier welfare.

Trade Extensions, CEO, Garry Mansell, said “Companies often talk about the ‘trust’ that exists between consumers and their brands and sometimes this ‘trust’ feels intangible. However, what this research shows us is when trust is broken, consumers let companies know very quickly by taking their custom elsewhere.”

In addition, consumers are also prepared to pay a premium if a retailer can demonstrate they treat their suppliers better than their competitors. Overall, 76% of consumers are willing to pay more and 28% will pay between 5% - 10% extra and 17% are prepared to pay an additional 10%.

Mansell said, “It is clear that consumers expect suppliers to be treated well and they are prepared to pay extra. Good buyers manage their suppliers in a sustainable way and while buyers and suppliers need each other, they both need the end consumers to be happy as well.”

-ends-

Editor’s Notes

The Trade Extensions ‘Research Bulletin’ series looks at sourcing and supply issues from the point of view of the end consumers and allows supply chain professionals to get into the mind of their ultimate customer.

Download the report here:

https://tradeextensions.com/s/Trade-Extensions-Research-Bulletin-October-2016.pdf

About Trade Extensions

Trade Extensions (www.tradeextensions.com ) specialises in strategic sourcing with optimisation and its platform, TESS™, is used to run projects ranging from routine sourcing, such as simple reverse auctions, to advanced projects involving goods and services worth billions of dollars, millions of data items and multiple rounds of negotiation. Over $1 billion worth of spend is allocated through TESS™ each week.

Trade Extensions has offices across Europe and the U.S. Its sourcing platform is used by leading companies including P&G, Tesco, Unilever, Cargill, Coca-Cola, Dow Chemicals, and Kimberly-Clark.

The Trade Extensions logo is a registered trademark of Trade Extensions TradeExt AB.

TESS™ and TESS Academy™ are trademarks of Trade Extensions TradeExt AB.

Contact:

Trade Extensions
Niklas Pettifor
nik.pettifor@tradeext.com
+44 (0)20 8004 3236

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye